CagriSema vs. Tirzepatide: Which One MELTS Fat Faster? | Dr. Dan | Obesity Expert
A 10-minute walkthrough of the REDEFINE 1 trial of CagriSema, with the host's comparison to tirzepatide. Includes sponsor and membership promos.
With Dr. Dan
Key moments
Tap a moment to play the video from there.
- 0:00Opening claim and the questionDan frames CagriSema as a new heavyweight and asks whether it beats Zepbound, citing the share of users who lost 20% and 25% of baseline weight.
- 0:49How CagriSema is builtDan explains that it combines semaglutide with the amylin analog cagrilintide. He says one handles hunger and the other handles feeling full.
- 2:47REDEFINE 1 trial designHe describes a 68-week phase 3 trial of 3,400 people with obesity and no diabetes, split into four arms with lifestyle counseling for all.
- 3:26Average weight loss by armDan reads out 20.4% for CagriSema, 14.9% for semaglutide, 11.5% for cagrilintide and about 3% for placebo. He says the combination is more than either alone but not simply additive.
- 4:35Share reaching large lossesHe says 54% of CagriSema users lost at least 20% of baseline weight, and describes nearly 20% as losing at least 30%.
- 4:55Body composition and other resultsDan says 67% of the loss was fat and 33% lean mass in a subset. He also cites lower blood pressure and blood sugar normalization in 88% of those with pre-diabetes.
- 6:25Side effects and safetyHe reports about 92% had some adverse event, mostly gastrointestinal, along with two unrelated deaths and dropout rates of about 6% versus 3.5% on placebo.
- 7:23Comparison with tirzepatideDan calls weight loss a dead heat. He says tirzepatide may be better for visceral fat and muscle preservation, while CagriSema may suppress appetite more.
- 8:37Closing view on CagriSemaHe concludes it is another effective option that works through a different pathway, and asks viewers whether they would switch or wait for long-term data.
What the video says
Dr. Dan, who presents as an obesity-medicine educator, uses this video to go through the REDEFINE 1 phase 3 trial of CagriSema, a combination of semaglutide and cagrilintide. He opens by asking whether the combination beats Zepbound (tirzepatide) and then explains how the two components are meant to work together. According to Dan, semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite, while cagrilintide is an amylin analog acting on the area postrema and hypothalamus.
Dan describes the trial as a global, 68-week study of 3,400 people with obesity and no diabetes. Participants were randomized to CagriSema, semaglutide alone, cagrilintide alone, or placebo, and all received lifestyle counseling that included a 500 calorie daily deficit. He reports average weight loss of 20.4% for CagriSema, 14.9% for semaglutide, 11.5% for cagrilintide and about 3% for placebo. He says 54% of CagriSema users lost at least 20% of baseline weight, and he describes nearly 20% as losing at least 30%.
On secondary results, Dan says that in a subset, 67% of the weight lost was fat mass and 33% was lean mass. He calls that reasonable for this level of loss but not ideal, and says tirzepatide studies showed about 25% lean mass loss. He also mentions lower blood pressure and says 88% of participants with pre-diabetes had their blood sugar normalize. On safety, he reports that about 92% had some adverse event, mostly nausea, heartburn, constipation and diarrhea. He says two deaths did not appear related to the drug, and that dropouts for side effects were about 6% on CagriSema and about 3.5% on placebo. He adds that mental health scores showed no worsening and that constipation seemed somewhat more common than in earlier GLP-1 studies.
Dan's comparison with tirzepatide is brief and based on his own reading. He says weight loss is roughly a dead heat, that tirzepatide may do better on visceral fat and muscle preservation, and that CagriSema may be stronger on appetite suppression. The video includes two sponsor or membership promotions and a pitch for paid channel membership, which take up part of the runtime.
On each compound
CagriSema0:00
Dan presents CagriSema as a semaglutide and cagrilintide combination and reports 20.4% average weight loss over 68 weeks in REDEFINE 1. He calls it an effective option that is not clearly superior to tirzepatide in every respect.
See how your DNA reads CagriSemaSemaglutide0:49
According to Dan, semaglutide is a GLP-1 receptor agonist that slows gastric emptying, reduces appetite and dampens the dopamine response to junk food. He reports 14.9% average weight loss for the semaglutide-alone arm.
See how your DNA reads SemaglutideCagrilintide1:02
Dan describes cagrilintide as an amylin analog that mimics the body's own amylin and acts in the area postrema and hypothalamus. He reports about 11.5% average weight loss for the cagrilintide-alone arm.
See how your DNA reads CagrilintideTirzepatide7:23
Dan says tirzepatide (Zepbound) is roughly equal to CagriSema on weight loss. He thinks it may be better for visceral fat and muscle preservation, citing about 25% lean mass loss in tirzepatide studies.
See how your DNA reads Tirzepatide“GLP1 says you're not actually that hungry and Amalin says also you're already full.”
What this video doesn’t settle
- The tirzepatide comparison is Dan's own reading across separate studies, not a head-to-head trial, and he does not cite the tirzepatide data in detail.
- The video gives no information on long-term outcomes beyond the 68-week trial, and Dan himself raises the need for longer data.
- Dan says the trial's two deaths do not appear related to the drug but gives no detail on how that was determined.
Questions this video answers
How much weight did people lose on CagriSema in the REDEFINE 1 trial?
Dan reports an average loss of 20.4% of baseline weight over 68 weeks, versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone and about 3% for placebo. He says 54% of CagriSema users lost at least 20%.
What are CagriSema's side effects according to Dr. Dan?
He says about 92% of participants had some adverse event, mostly nausea, heartburn, constipation and diarrhea. He reports dropouts for side effects of about 6% on CagriSema and about 3.5% on placebo, and says constipation looked somewhat more common than in earlier GLP-1 studies.
Is CagriSema better than tirzepatide (Zepbound)?
Dan says the two are in a dead heat on weight loss. He suggests tirzepatide may have an edge on visceral fat and muscle preservation and CagriSema on appetite suppression, and he does not call either one superior overall.
What is in CagriSema and how does it work?
Dan says it combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, an amylin analog. He describes the pair as reinforcing each other on hunger and fullness signals in the brain.
How much muscle is lost with CagriSema?
In a subset of REDEFINE 1, Dan says 67% of the weight lost was fat mass and 33% was lean mass. He calls this not ideal but reasonable given the amount lost, and contrasts it with about 25% lean mass loss in tirzepatide studies.
Video by Dr. Dan | Obesity Expert on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
